Patents by Inventor Kenneth A. Brasel

Kenneth A. Brasel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN GM-CSF ANTIGEN BINDING PROTEINS
    Publication number: 20130259799
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: June 11, 2013
    Publication date: October 3, 2013
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Nucleic acid molecule encoding human GM-CSF antigen binding proteins
    Patent number: 8481704
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: July 9, 2013
    Assignee: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • HUMAN GM-CSF ANTIGEN BINDING PROTEINS
    Publication number: 20130071923
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: August 20, 2012
    Publication date: March 21, 2013
    Applicant: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Human GM-CSF antigen binding proteins
    Patent number: 8268311
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: September 18, 2012
    Assignee: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • HUMAN GM-CSF ANTIGEN BINDING PROTEINS
    Publication number: 20110189082
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: September 18, 2008
    Publication date: August 4, 2011
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Methods of preparing dendritic cells with flt3-ligand and antigen
    Patent number: 7150992
    Abstract: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: December 19, 2006
    Assignee: Innunex Corporation
    Inventors: David H. Lynch, Kenneth A. Brasel, Hilary J. McKenna, Luis G. Borges, Charles R. Maliszewski, Eugene Maraskovsky